ClearPoint Neuro to acquire IRRAS for $5M cash + 1.325M shares; combined 2026 rev $54-60M

ClearPoint Neuro, Inc.

Total consideration: $5M cash plus 1.325M ClearPoint shares; earnout of 25% of net IRRA flow sales above thresholds.
IRRAS's IRRA flow catheter addresses ~400K US procedures/yr, targeting a $0.5B global intracranial bleeding market.
IRRAS has >50 active customers and 83% growth in first 9 months of 2025 to ~$9M revenue run-rate.
Combined entity expected to have 40+ additional commercial professionals; 2026 revenue guidance $54M-$60M.
Transaction approved by both boards; closing conditions include IRRAS stockholder approval and Nasdaq Stockholm delisting by Dec 31, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.